129 related articles for article (PubMed ID: 29250662)
1. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Significance of P53, C-MYC and BCL-6 Abnormality in Patients with Diffuse Large B Cell Lymphoma].
Chai CG; Zhang JJ; Li N; Cao L; Zhang SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):89-93. PubMed ID: 26913400
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
Takano Y; Saegusa M; Ikenaga M; Okayasu I
Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
[TBL] [Abstract][Full Text] [Related]
11. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
[TBL] [Abstract][Full Text] [Related]
13. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.
Suzuki M; Muroi A; Nojima M; Numata A; Takasaki H; Sakai R; Yokose T; Miyagi Y; Koshikawa N
Proteomics Clin Appl; 2020 Jan; 14(1):e1900091. PubMed ID: 31721454
[TBL] [Abstract][Full Text] [Related]
14. [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].
Weng Y; Gao ZF; Liu K; Zhang WJ; Ke XY; Li M
Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):681-3. PubMed ID: 16202261
[TBL] [Abstract][Full Text] [Related]
15. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
[TBL] [Abstract][Full Text] [Related]
16. Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.
Maartense E; Kramer MH; le Cessie S; Kluin-Nelemans JC; Kluin PM; Snijder S; Noordijk EM
Leuk Lymphoma; 2004 Jan; 45(1):101-7. PubMed ID: 15061204
[TBL] [Abstract][Full Text] [Related]
17. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
19. Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience.
Hu WM; Jin JT; Wu CY; Lu JB; Zhang LH; Zeng J; Lin SX
Diagn Pathol; 2019 Nov; 14(1):128. PubMed ID: 31711519
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].
Sun GX; Cao XS; Li Q; Wang ZL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Oct; 29(5):576-81. PubMed ID: 23042398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
